Par Calls Novartis' Lotrel Patent Unenforceable

Law360, New York (September 6, 2007, 12:00 AM EDT) -- Par Pharmaceutical Companies Inc. has fired off the latest salvo in its battle with Swiss pharmaceutical giant Novartis International AG over the billion-dollar hypertension drug Lotrel, asking a New Jersey court to declare a single Novartis patent covering the drug invalid and unenforceable.

Tuesday, Par filed an answer and counterclaims in the U.S. District Court for the District of New Jersey, alleging that Novartis had engaged in inequitable conduct before the U.S. Patent and Trademark Office, which Par says renders the patent-in-suit unenforceable.

“We continue to...
To view the full article, register now.